India's Dr Lal PathLabs rises; analysts back SN Genelab deal
BUZZ-India's Dr Lal PathLabs rises; analysts back SN Genelab deal ** Shares of Dr Lal PathLabs DLPA.NS rise as much as 1.3% to 1,986.80 rupees
** Diagnostics co will acquire a 70% stake in genomics-focused SN Genelab for 1.68 billion rupees ($17.52 million), plus up to 315 million rupees in performance-linked payouts
** Emkay raises PT to 2,100 rupees from 2,000 rupees, maintains "Buy"
** Emkay sees acquisition expanding DLPA's advanced genomics and molecular pathology portfolio, while offering cross-selling opportunities and geographic diversification
** Nomura ("Buy", PT: 2,150 rupees) sees marginal near-term earnings-per-share dilution from acquisition, but significant long-term upside as SN Genelab's testing capabilities scale through Dr Lal's network
** Twenty-five analysts have a "buy" rating; median PT is 2,025 rupees -- data compiled by LSEG
** YTD, DLPA up 30%
($1 = 95.9100 Indian rupees)
(Reporting by Urvi Dugar in Bengaluru)
Recent news on Dr. Lal PathLabs
See all newsBrief: Lal Pathlabs Says Unit Acquired Remaining 30% Equity Stake In Centrapath Labs Private Limited
India's Dr Lal PathLabs rises as Axis Securities initiates with 'buy'
India's Dr Lal PathLabs rises; analysts back SN Genelab deal
Brief: Lal Pathlabs Says Subsidiary Incorporated Dr Lal Pathlabs Indomed In Tashkent, Uzbekistan
India's Dr Lal PathLabs jumps to 4-year high after quarterly profit rise